Royalty Pharma RPRX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's net income?
- Royalty Pharma (RPRX) reported net income of $294.69M in Q1 2026.
- How has Royalty Pharma's net income changed year-over-year?
- Royalty Pharma's net income increased by 23.1% year-over-year, from $239.35M to $294.69M.
- What is the long-term trend for Royalty Pharma's net income?
- Over 3 years (2021 to 2025), Royalty Pharma's net income has grown at a 7.6% compound annual growth rate (CAGR), from $619.73M to $771.95M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.